^
    Back
    Association details:
    Biomarker:SS18-SSX fusion
    Cancer:Soft Tissue Sarcoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    S63845 (MCL1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Evaluation of combined BCL-2/MCL-1 inhibition as a therapeutic approach for synovial sarcoma.

    Published date:
    05/13/2020
    Excerpt:
    In vitro, SS all cell lines possessing the SS18-SSX fusion gene demonstrated synergistic sensitivity to combined S63845 and venetoclax, despite generally insensitivity to either drug as monotherapy. Importantly, in an SS PDX, we demonstrated S63845 and venetoclax synergize to induce tumor regression.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e23561